biotech · Breast Cancer · Advanced Breast Cancer · PBYI
PUMA BIOTECHNOLOGY
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology is a biotech organization headquartered in Los Angeles, USA. It trades on NYSE under ticker PBYI. Primary therapeutic focus areas include Breast Cancer, Advanced Breast Cancer, HER2+ Metastatic Breast
Company details
- Status
- Public
- HQ
- 10880 Wilshire Blvd, Los Angeles, CA 90024, US
- Founded
- 2010
- Employees
- 257
- Programs
- 40
- Drugs
- 23
- Patents
- 1
PUMA-ALI-1201
Phase 2 · small molecule · Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)
PUMA-ALI-1201 for Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC) is a Phase 2 program (small_molecule) at PUMA BIOTECHNOLOGY, INC. with 1 ClinicalTrials.gov record(s).
Internal code PUMA-ALI-1201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- PUMA BIOTECHNOLOGY, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)
- Status
- active
- Trials
- 1